Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab plus platinum-based chemotherapy in advanced or recurrent squamous NSCLC
2005-005533-35Phase 2Completed
- Sponsor
- Roche
- Start
- Apr 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of bevacizumab in Pulmonary squamous cell carcinoma (2 arms), sponsored by Roche. Primary endpoint: Grade ≥3 bevacizumab-related pulmonary hemorrhage rate. Started Apr 2006; status: completed.
02
Drugs
bevacizumab
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on 2005-005533-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005533-35.